Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registry
Almost half of all VHR patients with ASCVD and DM2 do not achieve current guideline lipid goals. Women, Black individuals, and those on Medicaid were significantly less likely to achieve these goals relative to their counterparts. Further targeted quality improvement interventions are needed to improve the equitable achievement of guideline-based lipid goals.
Authors
- Bethany Kalich (ORCID: https://orcid.org/0000-0002-1220-3484)
- Peter Shrader
- Nafeesa N Dhalwani (ORCID: https://orcid.org/0000-0003-3204-1328)
- Satoshi Shoji (ORCID: https://orcid.org/0000-0002-2223-7215)
- Laine Thomas (ORCID: https://orcid.org/0000-0002-5340-8742)
- Ann Marie Návar (ORCID: https://orcid.org/0000-0002-6197-9860)
- Nishant Shah (ORCID: https://orcid.org/0000-0002-2666-7132)
- Neena Thomas
- Cezary Wójcik (ORCID: https://orcid.org/0000-0003-2509-7251)
- Eric David Peterson (ORCID: https://orcid.org/0000-0002-5415-4721)
- Jonathan Arnold
- Elisa L. Priest (ORCID: https://orcid.org/0000-0003-0474-6275)
- Mahanaz Syed
Institutions
- Amgen (United States) (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Pittsburgh (US)
- Duke University (US)
- Keio University (JP)
- Clinical Research Institute (US)
- Southwestern Medical Center (US)
- Baylor Scott & White Health (US)
- The Ohio State University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1016/j.ajpc.2024.100921
- Citations
- 5
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Amgen
- Esperion Therapeutics